Replimune Group, Inc. (REPL)
NASDAQ: REPL · Real-Time Price · USD
8.41
+0.80 (10.51%)
At close: Apr 2, 2026, 4:00 PM EDT
8.43
+0.02 (0.24%)
After-hours: Apr 2, 2026, 7:39 PM EDT
Replimune Group Market Cap
Replimune Group has a market cap or net worth of $694.44 million as of April 2, 2026. Its market cap has decreased by -21.59% in one year.
Market Cap
694.44M
Enterprise Value
501.64M
1-Year Change
-21.59%
Ranking
Category
Stock Price
$8.41
Market Cap Chart
Since July 20, 2018, Replimune Group's market cap has increased from $467.51M to $694.44M, an increase of 48.54%. That is a compound annual growth rate of 5.27%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 2, 2026 | 694.44M | -8.92% |
| Dec 31, 2025 | 762.47M | -18.18% |
| Dec 31, 2024 | 931.93M | 87.18% |
| Dec 29, 2023 | 497.87M | -67.63% |
| Dec 30, 2022 | 1.54B | 21.04% |
| Dec 31, 2021 | 1.27B | -27.53% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Jul 20, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| SELLAS Life Sciences Group | 741.68M |
| Solid Biosciences | 736.95M |
| Relmada Therapeutics | 733.18M |
| BridgeBio Oncology Therapeutics | 713.09M |
| Arvinas | 693.98M |
| Design Therapeutics | 692.58M |
| Alto Neuroscience | 692.58M |
| Bright Minds Biosciences | 689.00M |